GlassScriptPhysician profile
Mark David Kinkel
NPI 1952185894
$5,665.60
in general payments reported to CMS, 2019-2025
27 companies · $2,810 in 2025
The $2,810 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $332 · 2024: $2,524 · 2025: $2,810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,653 · Education: $12.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,653.18 |
| Education | $12.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,562.15 | 2023-2025 | Rukobia, Dovato, Cabenuva |
| Gilead Sciences, INC. | $1,324.12 | 2023-2025 | Yeztugo, Biktarvy, Sunlenca |
| Novo Nordisk INC | $682.62 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Theratechnologies INC. | $493.06 | 2023-2025 | Egrifta, Trogarzo, Egrifta Sv |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $274.86 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $257.31 | 2023-2025 | Pifeltro, Capvaxive, Delstrigo |
| Amgen INC. | $188.52 | 2024-2025 | Otezla, Repatha, Repatha |
| Emd Serono, INC. | $159.92 | 2024-2025 | |
| Lundbeck LLC | $86.71 | 2024-2025 | Rexulti |
| Abbvie INC. | $69.17 | 2024-2025 | |
| Napo Pharmaceuticals INC | $65.27 | 2025 | Mytesi |
| Exact Sciences Corporation | $58.98 | 2024-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $55.78 | 2023-2025 | Auvelity |
| Aimmune Therapeutics, INC. | $49.12 | 2025 | Zenpep |
| Lilly USA, LLC | $47.41 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.27 | 2024 | Xifaxan |
| Verity Pharmaceuticals INC. | $41.69 | 2025 | Tlando |
| Astrazeneca Pharmaceuticals LP | $34.44 | 2024-2025 | Airsupra, Farxiga |
| Hologic Sales and Service, LLC | $29.58 | 2025 | Aptima |
| Takeda Pharmaceuticals U.S.A., INC. | $24.44 | 2023 | Takhzyro |
| Phathom Pharmaceuticals, INC. | $21.09 | 2024 | Voquezna |
| Alvogen INC | $17.13 | 2025 | Teriparatide |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.12 | 2024 | Jardiance |
| Sumitomo Pharma America, INC. | $16.62 | 2023 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $16.61 | 2024 | |
| Tolmar, INC. | $14.79 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $13.82 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kinkel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.